Pharma News
Adalimumab biosimilar by Biocon for Plaque Psoriasis (Psoriasis Vulgaris): Likelihood of Approval
Adalimumab biosimilar is under clinical development by Biocon and currently in Phase III for Plaque Psoriasis (Psoriasis Vulgaris).
Source link
#Adalimumab #biosimilar #Biocon #Plaque #Psoriasis #Psoriasis #Vulgaris #Likelihood #Approval